Response to Pralsetinib Observed in Meningeal-Metastatic EGFR-Mutant NSCLC With Acquired RET Fusion: A Brief Report

Response to Pralsetinib Observed in Meningeal-Metastatic EGFR-Mutant NSCLC With Acquired RET Fusion: A Brief Report

Introduction: RET is well known as an important driver gene in NSCLC. Moreover, RET is a rare acquired resistance mechanism to EGFR-mutant NSCLC. Only 36 NSCLC cases of coexistence of EGFR and RET were reported previously worldwide. So far, there have been no reports on the following: (1) whether co...

Full description

Bibliographic Details
Main Authors: Zichen Zhao, MD, Chao Su, PhD, Weigang Xiu, MD, Weiya Wang, MD, Shasha Zeng, MD, Meijuan Huang, MD, Youling Gong, MD, You Lu, MD, PhD, Yan Zhang, MD, PhD
Format: Article
Language:English
Published: Elsevier 2022-06-01
Series:JTO Clinical and Research Reports
Subjects:
EGFR
RET fusion
Lung cancer
Meningeal metastasis
Pralsetinib
Cerebrospinal fluid
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364322000674

Internet

http://www.sciencedirect.com/science/article/pii/S2666364322000674

Similar Items